Mortality in Patients with Basal and Squamous Cell Carcinoma

mortality

There are varying reports of the association of basal cell carcinoma and cutaneous squamous cell carcinoma with mortality. A recent review looked at the all-cause mortality of the general population after a diagnosis of basal cell carcinoma or squamous cell carcinoma.

Continue reading “Mortality in Patients with Basal and Squamous Cell Carcinoma”

Most Effective Treatment for Superficial Basal Cell Carcinoma

superficial basal cell carcinoma

A variety of non-invasive treatments are available in the treatment of superficial basal cell carcinoma. A study looked at three different methods to determine the most effective approach after one, three and five years: photodynamic therapy, topical imiquimod or topical 5-fluorouracil. Continue reading “Most Effective Treatment for Superficial Basal Cell Carcinoma”

Can a course of fluorouracil cream reduce a person’s risk of BCC and SCC?

fluorouracil

This month’s paper from JAMA Dermatology, by Weinstock et al, is instructive. The authors did a randomised trial of five per cent fluorouracil cream applied to the face, to see if a two to four week application would reduce the number of basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) in the following year. Continue reading “Can a course of fluorouracil cream reduce a person’s risk of BCC and SCC?”

Skin Cancer Update with Prof Giuseppe Argenziano [April 2018]

skin cancer update APR18

In this month’s skin cancer update, Professor Giuseppe Argenziano discusses melanoma that arise within pre-existing congenital naevi.

The risk of melanoma arising out of large congenital naevi in a person’s lifetime is 1 in 10. The risk in intermediate congenital naevi is 1 in 200 and the risk in small congenital naevi is 1 in 200,000. Thus, the risk increases with the size of the naevus. Continue reading “Skin Cancer Update with Prof Giuseppe Argenziano [April 2018]”

How can computer vision aid in melanoma detection?

computer vision

How can computer vision aid in melanoma detection? A study recently published in the Journal of the American Academy of Dermatology compared the diagnostic accuracy of computer algorithms to dermatologists using dermoscopic images.

The study involved 100 randomly selected dermoscopic images comprising of 50 melanomas, 44 naevi, and six lentigines. Researchers used both non-learned and machine learning methods to combine individual automated predictions into “fusion” algorithms. In a companion study, eight dermatologists classified the lesions in the 100 images as either benign or malignant. Continue reading “How can computer vision aid in melanoma detection?”

Gefitinib for Incurable, Recurrent or Metastatic Squamous Cell Carcinoma

gefitinib

A recent study looked at the efficacy of gefitinib in patients with cutaneous squamous cell carcinoma (SCC) whose cancer was not amenable to curative therapy including surgery or radiation.

The epidermal growth factor receptor plays a key role in the carcinogenesis of SCC. However, there are limited data on the efficacy of epidermal growth factor receptor inhibitors in incurable, recurrent and/or metastatic SCC. Continue reading “Gefitinib for Incurable, Recurrent or Metastatic Squamous Cell Carcinoma”

A New Way to Evaluate Acral Lesions

lesions

This month’s article is an editorial in the British Journal of Dermatology by Tschandl and Wiesner, that explores recent advances in aspects of imaging of pigmented skin lesions.

It is a quick, worthwhile read to consider recent developments. My primary reason for highlighting this article this month, however, is because it includes work by Lallas et al mentioning a new way to evaluate acral lesions. Continue reading “A New Way to Evaluate Acral Lesions”

Skin Cancer Update with A/Prof Giuseppe Argenziano [March 2018]

skin cancer update

In this month’s skin cancer update, Associate Professor Giuseppe Argenziano discusses vulvar mucosal lesions. These pigmented lesions can be difficult to manage because they often look very irregular and fit the ABCD criteria for melanoma.

Giuseppe explains that with vulvar lesions, we should avoid applying the same rules that typically apply to the rest of the body concerning the clinical diagnosis of melanomas. Continue reading “Skin Cancer Update with A/Prof Giuseppe Argenziano [March 2018]”

Immunotherapy Replacing Chemotherapy in Melanoma Treatment

immunotherapy

Chemotherapy could become a thing of the past for up to two thirds of cancer patients, as the federal government considers subsidising new immunotherapy treatments.

Immunotherapy treatments Optivo and Keytruda are already subsidised by the government for the treatment of patients with melanoma, lung cancer and kidney cancer. Seeking subsidisation is a slow process that has denied treatment to patients with other cancers who cannot afford therapy. Continue reading “Immunotherapy Replacing Chemotherapy in Melanoma Treatment”

Regular Sunscreen Use Could Reduce Melanoma Rates by a Third

sunscreen

If all Australians regularly applied sunscreen, the burden of melanoma could be reduced by up to 34 per cent by 2031, according to a study by the QIMR Berghofer Medical Research Institute.

In a study published in the British Journal of Dermatology, researchers predicted the likely impact of regular sunscreen use on melanoma rates. They found that 28,071 fewer melanomas would be diagnosed in Australia over the next 13 years if everyone frequently wore sunscreen. Continue reading “Regular Sunscreen Use Could Reduce Melanoma Rates by a Third”